Tofacitinib Extended-Release is a medication used in this trial to treat inflammatory arthritis. It works by reducing inflammation and pain in the joints. The trial is investigating whether taking this medication in the morning or evening is more effective in managing the symptoms of arthritis.

Rheumatoid Arthritis – Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints. It occurs when the immune system mistakenly attacks the body’s own tissues, leading to joint pain, swelling, and stiffness. Over time, it can cause joint damage and deformities. The disease often starts in smaller joints, such as those in the fingers and toes, and can progress to larger joints like the knees and hips. Symptoms may vary in severity and can come and go, with periods of increased disease activity known as flares. It can also affect other parts of the body, including the skin, eyes, lungs, and blood vessels.

Psoriatic Arthritis – Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis, a condition characterized by red patches of skin topped with silvery scales. It involves joint pain, stiffness, and swelling, which can affect any part of the body, including the fingertips and spine. The disease can range from mild to severe and can worsen over time. Symptoms may include swollen fingers and toes, foot pain, and lower back pain. Like psoriasis, psoriatic arthritis is a chronic disease that can have periods of remission and flare-ups. It is an autoimmune condition, meaning the immune system attacks healthy cells and tissues.